New TRITON analysis shows further benefits for prasugrel
This article was originally published in Scrip
Executive Summary
A new analysis of data from the Phase III TRITON-TIMI 38 trial has shown that patients receivingDaiichi Sankyo/Lilly's platelet inhibitor prasugrel (Effient) who survived their first cardiovascular event were 35% less likely to suffer a similar recurrent event than those on clopidogrel (Sanofi-Aventis's Plavix/Iscover).
You may also be interested in...
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Genmab buys into ADCs; Roivant set to take on AbbVie in uveitis; Ipsen signs firs ADC pact; South Korea looks to build biotech momentum; and the end of the road for Acorda.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Merck & Co progresses cardiovascular strategy; Novo purchase builds heart failure presence; CRL setbacks for Regeneron; ITF faces challenging Duchenne field; and AbbVie needs to freshen up.